Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trying to pick up another 10k shares today! Always a challenge trying to get more!
Yes makes sense, some of the smartest people left other successful companies to come to Inmed and be a part of a dump scam! Not a pump and dump because they don't pump. A dump! Inmed's Glaucoma and Biosynthesis patents aren't approved yet but they're moving forward! Not worried here!
Glaucoma has enough sufferers for multiple companies drugs to succeed!
More filings coming in regards to this minor! There is a reason they're silent! Plus they don't need approval to sign licensing contracts! HB, when you exit at $1.00 or $2.00? Just don't look back!
I'm assuming because Inmed doesn't need to be at commercial scale to Biosynthesize cannabinoids for their own drugs. Plus Inmed is partnered with UBC. They can produce this minor at bench scale for sure. Remember what A. Mancini said. CBD doesn't have anything on this minor cannabinoid. Not those exact words. Lol
There actually is something to be tight lipped about and it's the minor cannabinoid in Inm-755. The same one Inmed will be commercializing while the yeast companies are still trying to commercialize CBD. This said, if this makes another run north of a dollar with nothing concrete backing it up? I will be quick to the sell button or if they delay 755 clinical trials in the next qtr report? I'll be even quicker to the sell button. Next 6 months will be big and telling.
I personally think if Eric Adams and company's sole purpose was to dump their shares when this hits a dollar or two ? They would've been pumping this for a while because that's their goal! Not a word from them in months tells me something different than most. They're being very tight lipped about something. They're focused on something! Not because they have nothing to share but because what they share next will be big! Not only that, I truly believe our partner is Lilly! My point being most people see this silence as bad and the company is hiding but I see it totally opposite! There's a reason for it! I think we'll be singing a different tune by years end! IMHO!
How is volume only at 100 4 hours into the trading day? I also noticed you only get news releases if you joined their email list. I can't find any past news on my Ameritrade account. This stock is definitely a nice little secret!
How are you LB? Yes still holding strong! I believe big things coming by years end and beginning of 2020. I also wish I knew when to sell when the peaks hit! If we all knew? We'd all be rich! Lol.
I took a big puff, thanks Matilda! You have a great evening also!
Yes I did! This company is full of professionals! Very experienced professionals! Eric Adams didn't sell because he's scamming the shareholders! He knew the stock prematurely hit $2 and took some profit but everyone always crushes him for it! This is a Biotech company in a brand new industry. There will be hurdles and delays! Guaranteed. I have a strong feeling they have the 755 formulation pretty much dialed in! They have a lot of incentives to hit which requires them to start getting the SP up! Tech transfer is complete, they're in the middle of scaling up. Now I just think it's about figuring out yields and costs. JMO but I think Inmed is real close to some big news coming our way by end of this year! Reading between the lines, I've seen progress over the last year! Let the next 6 months play out and see where we are!
INM-755 Will be in clinics by end of the year! I think they would have delayed already if that was going to happen! If Inmed does delay again for another year? I will be out for good!
Do you really think come by end of this year Inmed will delay Clinical trials again and there still won't be any updates regarding Biosynthesis? No way in hell I'm being caught on the sidelines when this news breaks! Plus if ph 1 and ph 2 Clinical Trials are successful with Inm-755 using the minor cannabinoid? That's proof of the medicinal powers of it!
I'm glad I sold this stock a long time ago! Brutal.
I agree Shermann7, yesterday morning I put my Limit order in at .1750 even though the SP was .1730. My order wouldn't fill. Actually the day before my order expired, I also had the limit order set a bit higher. So I knew it wasn't going to fill so I changed my limit to .19, then it filled immediately. These shares are going to be hard to come by!
I have a nice starting position here now. Just going to hold on to this baby as long as it takes! Very excited for this tech and potential! I really believe we are at the bottom here between .16 - .19 U.S. GL!
I'm taking a nice position Monday morning! The future is bright here!
I think this company is going to be huge!
That's the price of getting in this low! All these new Biosynthesis companies have nothing but potentials! Inmed just has way more than most others at this stage!
I'm thinking opposite! If they weren't accomplishing anything? They wouldn't of let the May warrants expire! Or the July ones coming up. They'd be pumping to get their hands on that extra cash! They're being silent for a reason. I think they know what's coming!
What does everyone expect from Inmed? This is a pre-clinical company that's ready to become a clinical company within the next 6 months! Their tech transfer is complete! They're executing. Everyone expects this to explode over night perfectly with no delays and no hiccups. BTW, this team they have assembled? They wouldn't be here now still working together if things weren't moving along beautifully! It cracks me up with all the complainers saying this is worthless and a joke! Speaking for myself, I'm exited as heck for the next year. This rare cannabinoid that's in Inm-755 could potentially be HUGE! Plus Inmed will be commercially producing that cannabinoid probably 10× the value of CBD&THC. Oh ya, while Inmed will be signing contracts with other pharma companies using that rare cannabinoid? The yeast companies will still be pumping and fighting with each other scaling up CBD and THC! Bring it on. If this drops in the .20's? I will be very happy to add as many shares as I can. I've been accumulating while every one bitches and complains!
You think this is Tim's first trade? Lol, you have no idea what he does for a living do you?
Thanks Les! That was a great post by a very knowledgeable man. Now it looks like Michael Woudenberg was granted options. I think it's a good sign the whole team is being granted options! The SP diving right now has nothing to do with what Inmed is accomplishing behind closed doors! Only a matter of time!
I shared that post from a friend!
Just speculating ... but F*** what do we really have? ... a lot.
In the beginning, God created the Heavens and the Earth and all that they contain. And that was good. Arbitrarily, Man decided that some of it was not good and made laws.
I like line one and not so much line two.
If I were a UFO conspiracy theorist, I would think that aliens placed genetically engineered beings on earth and created cannabis to be the substance that regulates their mental and physiological well being.
Deep....
Well, some humans decided that cannabis is not good, and this is where we stand. Thou shalt not do marijuana.
Boy, I am glad that Dr. Sazzad Hossein believed in "Nature" and not "Man"
Now we need to think about just exactly what Dr. H has discovered. Publically, we don't know what InMed knows but we can extrapolate a strategy.
It was never about CBD or THC.
If you are a company doing research on how to cure people, your first objective is understanding "what" cures people and then business people ask how much does it cost. Obviously, the researcher will also ask the same question because they need access to the substance to do the research.
Think about the chicken and the egg - "why is biosynthesis important?" THC and CBD are in enough abundance that the curing substance is financially accessible. So why bother with biosynthesis?
Because Dr. H. knew something. He knew something important. He knows something few other cannabis researchers knows. He knows what minor cannabinoids do so he also needed to know how to make them accessible.
STOP HERE and think about this. Anyone can know about what they can test in the real world. But how can someone know about something you cannot test?
HUH.
There must be some scientific knowledge we do not have access to that InMed does.
I really don't know what cannabinoid they are researching for EB but it is now obvious that it would have limited accessibility if it was too expensive. Biosynthesis solves that whether it is through yeast or ecoli. Keep this in mind.
I have no evidence or literature to share but I have a theory everyone should look into. An understanding of what the minor cannabinoids MIGHT BE ABLE to do is a very powerful value creator. If Dr. H correctly identified EB, Glaucoma, and Orofacial Pain as addressable with minor cannabinoids, what else in the bioinformatics database?
Hmmmm.
I commented in another post that CBD and THC have thousands of patents but the minor cannabinoids have a very small number.
Anecdotal evidence tells me that there is BIG interest in a certain minor cannabinoid - BTW - not going to disclose until InMed files patents on it. I'm not going to give hints to the competition.
So, WTF is this post about? The unkown is interesting and good. Cannabinoid manufacturing will become ubiquitous but it is the focus on the minor cannabinoids that will create value. A lot of value. Investing in knowledge is a good strategy.
Dr. H was/is amazingly ahead of the world on this. There is more here than meets the eye of the analyst. Eventually, they will catch up but in the meantime, God Bless Dr. H. and Stay Thirsty My Friends.
#STMF
Warrants are a very risky investment. Way more risky than buying common shares. When you buy warrants you are potentially buying shares way cheaper now than paying higher future price. But remember the company owes warrant holders nothing. If they don't need the funding or they don't have the SP at the exercise price? Warrant holders lose everything. You can try to sell warrants but it's a lot harder the closer you get to the expiration date. If you don't own these Warrants that expire in July? It's not bad if they expire because less dilution meaning our shares are potentially more valuable. If we get there organically with real news? Great! If not, Inmed isn't desperate because big things are coming!
Yes I can!! It's a rare and very valuable cannabinoid!
Exactly Les, the possibilities are endless. I truly believe we are ahead of the market with this brand new sector. Inmed is playing chess right now. Just getting their pieces in place for success!
Shared post!
It Sucks being Ahead of Everyone
There are many lonely places to be and some are more stressful than others.
The North Pole - no heat, no plumbing
Death Valley - name kind of says it all
The CEO's office - can't discuss fears and doubts with either your board or staff or you will lose confidence and your job
The investor ahead of the market - ... where the fudge is everyone?
So what am I getting at?
I'm sorry to say that all of us here who are invested in InMed are the smart kids that many of us tormented in high school. The cool kids got shitty marks and made fun of the egg heads. It's easy to criticize but eventually the "cool kids" come around and say "yeah, I knew it all along."
Fuc*'m all. It's a lonely place to be but eventually, the world catches up.
So what am I talking about?
Buckle up.
1. 755 is a single rare cannabinoid: WTF?
Well, I'll tell you the WTF.
First, screw the world! We want to be alone! We want no competition! We want to be in a place where no one can play with us unless we invite them. There is nothing unique about CBD. It's boring. it is being chased by everyone and everything is out in the open. There are over a thousand patents/applications on CBD. There is over 5 thousand on THC. All of the "cool" companies are chasing after the main-stream bullpuckies.
Being different is good. Being better and different? You know the answer to that.
I have no idea what "rare" cannabinoid InMed is considering, but CBD + THC is 6,000+ patents.
CBGA has 43 patent/applications. FORTY THREE with only ONE disease, illness indication. Why? Likely it is because no one can afford the cost. InMed can afford to do the research because of their bench-scale manufacturing capability.
2. Bench-scale manufacturing ability.
Research that only the loneliest can do baby! I don't care if the Yeasty Boys get better. If InMed is focused on taking their bench-scale manufacturing ability to file research patents on cannabinoids that no one can afford to study. InMed will have portfolio of trade secrets that will take decades for others to catch up to. Yeast needs to be genetically modefied for each cannabinoid. InMed's tech might be able to do them all.
Damn!
Alone again!
3. OK - F**king obvious. InMed can do real research with cannabinoids no one else can get their hands on.
4. The Clean Room!
Do not under-estimate this comment from Eric Adams in the conference call. This is a powerful concept. The most expensive city (I think) is Manhattan. If you are going to make meatballs, it is better to make them in Missouri and ship them to Manhattan than make them in Manhattan and ship them to Missouri. But if you HAVE to make them in Manhattan, the shorter the time you need to manufacture the better. There isn't much profit margin in Manhattan but lots in Missouri because of the price of real estate.
The clean room = Manhattan.
Yeasty Boys - slow and same yield.
Just my opinion but that sounds like a crappy investment.
5. Pharmaceutical Applications:
Yeast, schmeast. So you can make a cheap cannabinoid. BFD. Who is going to make money off of your "cheap cannabinoid"?
All of the companies that are doing cannabinoid research are going to make money AFTER the rare cannabinoids become commoditized.
6. Building value - I don't really care what the yeasties or any other bullpuckie biosynthesis claimants are jerking each other off about. They do not have the capabilities to take their product and add value to the greater good of mankind. They need a preclinical and clinical team of experts. They could also use a bioinformatics database. Otherwise, they are just selling a commodity.
Damn. It is hard being alone and unloved.
It is really hard knowing that you are smart, pretty, handsome, a great conversationalist, creative, innovative, a great cook and able to make our own super funky clothes. We can even play bass, drums and keyboards for the garage band.
Oh yes, we also have the most awesome ass anyone has ever seen. It will just take a bit time before everyone is gawking at it.
There is nothing more lonely than beng alone!
#STMF
"We see benefits in what we have chosen that goes beyond what CBD can offer!"
"Alex Mancini"
Inm-755 not using CBD but rather a rare cannabinoid. Unnamed partner is a well Established company. Inmed still owns all rights to their technology. A lot of positives today! Haters can hate. Patience and a vision will pay off.
Above post I'm sharing from a very respected FB member.
Hi Everyone. It's a new Era!
A couple of hours ago, Japan entered into a new era. The first day of the Reiwa Era is May 1st and there are lots of things to look forward to.
For us, it is a good time to reflect on where we've come and where we are going.
May 21, 2014 InMed commences trading on the CSE as Cannabis Technologies. They rebrand to become InMed technologies in March 2015 and focus on a potential unicorn application in EB. In August 2015, they have a positive test result for their invitro preclinical experiment in EB. Also in 2015, they initiate experimentation on Oral Facial Pain and file provisional patents for treating eye diseases using cannabinoids.
2016 was the return from the edge of the abyss with the decision to press forward with their biosynthesis technology and the appointment of Eric Adams as the CEO. This is when things got interesting. The ecoli biosynthesis platform was thought to be impossible but the research group working with InMed and the University of British Columbia had a break through. Eric rolled up his sleeves and filled the company with enough cash to get the programs to survive another day. He built the team through 2016 with the addition of the CFO and VP Regulatory affairs. He continued to find money for the company and put InMed on solid ground.
2017 was the first transformational year with the appointment of Eli Lilly's Martin Bott to the Board of Directors. This, in my opinion was the validation that ecoli biosynthesis was real and real important. Also, InMed files the PTC for EB and the company is well on the way. For much of the year, the CEO is on the road promoting the company and gaining momentum. He presented at several conferences and raised significant capital enabling the development of a clinical pathway for EB and progress on the preclinical pipeline. Also in 2017, InMed files the Biosythesis patent, hires Ben Patterson formerly of Eli Lilly to take the manufacturing technology to commercialization.
But InMed wasn't finished. They appointed the world famous cannabis researcher Dr. Mauro Maccarrone to the Scientific Advisory Board, filed the provisional patent for Oral Facial Pain and announces positive preclinical data on "... an Ocular Hydrolgel Formulation using a Biosynthesized Cannabinoid" on October 24, 2017.
Boy did 2018 ever start with a bang! Riding the cannabis wave, InMed skyrocketed prematurely to over C$2 and set somewhat unrealistic expectations that extend to this day. Also exciting was the filing of the biosynthesis patent, partnering with the National Research Council of Canada to help scale up of biosynthesis, the contract with an undisclosed Contract Research and Development Organzation to help with purification and subsequent manufacturing once scale-up is complete. Inmed closed the year with $20+ million in the bank and 2 years on runway to get to biosynthesis commercialization and phase II clinical trials for EB.
The foundation has been build and now the next Era is at our doorstep. This year, InMed Pharmaceuticals will enter into a new era of becoming a Clinical Stage Biopharma Company and a commercial plan for revenues in earl 2020.
Life is good. Cash in bank. Patents filed. Partners lined up. InMed is in execution mode and that is an exciting place to be. There is good news to come for those with patience.
#STMF
Thats funny, when something is Toxic? What is human nature? To get as far away as possible right? But you seem to stay as close to Inmed as you can! Thanks, I'm adding more Imlff today!
You throw stones at things you're scared of!!
I get a strong feeling that our unnamed partner is a multi billion dollar MC company. Inmed knows this, that's why there is no need to just pump out PR's! I'm staying patient as long as it takes. The announcement will come. No doubt. All this silence is for a reason!
Plus Inmed has a new CEO since 2015. Plus talking to a very well informed investor and professional told me that going to a one cannabinoid formulation was genius! FDA approval just became a lot more possible! Plus they're not tinkering with it. They know what they have! The gentleman they brought on Steven Dinh is an expert in this field also! These people know way more than these posters on message boards expressing their own 2 cents!
YESTERDAY!
Does Roth Capital have that much influence?